Heron Therapeuti Stock Today
| HRTX Stock | USD 1.06 0.06 5.36% |
Performance0 of 100
| Odds Of DistressOver 83
|
Heron Therapeuti is trading at 1.06 as of the 21st of November 2024; that is 5.36 percent decrease since the beginning of the trading day. The stock's open price was 1.12. Heron Therapeuti has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Heron Therapeuti are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of August 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of August 1987 | Category Healthcare | Classification Health Care |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 152.1 M outstanding shares of which 28.81 M shares are currently shorted by private and institutional investors with about 20.19 trading days to cover. More on Heron Therapeuti
Moving together with Heron Stock
Moving against Heron Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Heron Stock Highlights
| CEO Director | Craig Collard | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHeron Therapeuti can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Heron Therapeuti's financial leverage. It provides some insight into what part of Heron Therapeuti's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Heron Therapeuti (HRTX) is traded on NASDAQ Exchange in USA. It is located in 4242 Campus Point Court, San Diego, CA, United States, 92121 and employs 126 people. Heron Therapeuti is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 170.35 M. Heron Therapeuti conducts business under Biotechnology sector and is part of Health Care industry. The entity has 152.1 M outstanding shares of which 28.81 M shares are currently shorted by private and institutional investors with about 20.19 trading days to cover.
Heron Therapeuti currently holds about 83.54 M in cash with (58.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check Heron Therapeuti Probability Of Bankruptcy
Ownership AllocationHeron Therapeuti has a total of 152.1 Million outstanding shares. The majority of Heron Therapeuti outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Heron Therapeuti to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Heron Therapeuti. Please pay attention to any change in the institutional holdings of Heron Therapeuti as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Heron Ownership Details
Heron Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-06-30 | 3.1 M | |
| Jw Asset Management, Llc | 2024-09-30 | 2.3 M | |
| Orchard Capital Management, Llc | 2024-06-30 | 2.2 M | |
| Renaissance Technologies Corp | 2024-09-30 | 2 M | |
| Congress Park Capital Llc | 2024-09-30 | 2 M | |
| Tang Capital Management Llc | 2024-06-30 | 1.9 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.8 M | |
| Monaco Asset Management | 2024-09-30 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | |
| Rubric Capital Management Lp | 2024-06-30 | 26.7 M | |
| Vanguard Group Inc | 2024-09-30 | 8.7 M |
Heron Therapeuti Historical Income Statement
Heron Stock Against Markets
Heron Therapeuti Corporate Management
| PharmD D | Executive Officer | Profile | |
| Barry PharmD | Chairman CEO | Profile | |
| Lisa Peraza | VP Officer | Profile | |
| Chris Storgard | Chief Officer | Profile |
Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.